Additionally, SMAD4 alterations in the TGF-Beta pathway (p = 0.08) were slightly more frequent in H/L patients, pointing to a potential role for TGF-Beta signaling in GC pathogenesis in this population. This evidence concerns the gene SMAD4 and gastric cancer.